Navigation Links
Alzheimer's disease therapeutic prevents long-term damage from TBI in pre-clinical studies
Date:3/15/2009

WASHINGTON, D.C. A class of Alzheimer's disease drugs currently studied in clinical trials appears to reduce damage caused by traumatic brain injury in animals, researchers at Georgetown University Medical Center report in an upcoming advance online publication of Nature Medicine.

They say the results suggest that this class of drugs could potentially do something no other drug has been able to do-- prevent the long-term and continuing damage that often follows a serious injury to the brain.

That is because the agents, known as gamma secretase inhibitors, are designed to prevent build-up of amyloid, a toxic peptide found in the brain. This peptide clogs the brains of Alzheimer's patients but it is has also been found in people who have died from traumatic brain injury, says the study's lead author, neuroscientist Mark Burns, PhD, an assistant professor at GUMC.

"No one knows why it occurs, but abnormal amounts of amyloid plaque have been found during an autopsy in about a third of brain injury victims, some of whom were children who would ordinarily never have had these deposits," says Burns. "Remarkably, these deposits may occur in less than one day after injury."

There is another connection between traumatic brain injury and Alzheimer's disease, he says it is known that people who suffered a brain injury had a 400 percent increased risk of developing the disorder.

"But up until now, these were just interesting observations," Burns says. "In this study we show that the same pathways activated chronically in Alzheimer's disease are activated acutely in traumatic brain injury and that they appear to play a very important role in secondary injury."

Severe brain injury usually produces an immediate "necrotic" death of nerve cells, but this damage is often followed by a secondary wave of injury that can last weeks, months, and even years, Burns says. This damage comes from apoptosis, which is a differ
'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
215-514-9751
Georgetown University Medical Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Paradigm shift in Alzheimerss research: new treatments
2. Iron is involved in prion disease-associated neuronal demise
3. Seeing stem cells helps in fight against peripheral arterial disease
4. Metastatic bone disease patients can walk in Lazarus footsteps
5. Pitt researchers describe molecular 2-step leading to protein clumps of Huntingtons disease
6. Stem cell breakthrough gives new hope to sufferers of muscle-wasting diseases
7. Computer superpower strengthens attempts to combat common diseases
8. Cats eye diseases genetically linked to diseases in humans
9. New discovery paves the way for new diagnosis of serious lung disease
10. Addiction: Insights from Parkinsons disease
11. Portable kit may 1 day detect plant disease before disastrous outbreak
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/15/2014)... nanoparticle form could help reduce side effects by targeting ... scientists have developed nanoparticles that deliver one or two ... design particles that can carry any more than that ... devised a new way to build such nanoparticles, making ... drugs. In a paper published in the Journal ...
(Date:4/15/2014)... temperatures in the Congo Basin to increase by ... by greenhouse gases by half, according to a ... Belgium. , Explosive population growth and inefficient agricultural ... in Central Africa. A team of researchers from ... will affect longer-term temperatures in the region. Using ...
(Date:4/15/2014)... systems soon could be powering the forklifts used in ... with faster refueling times than ever before, courtesy of ... Carriers (HHC). , The goal of the project is ... refuel at low pressure four to five times faster ... hydrogen a competitive advantage over batteries for a big ...
Breaking Biology News(10 mins):Targeting cancer with a triple threat 2Targeting cancer with a triple threat 3Study: Deforestation could intensify climate change in Congo Basin by half 2Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 2Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 3Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 4
... intelligent prey such as monkeys which have exceptionally large ... The study, carried out by Dr Susanne Shultz, from ... Africa and South America such as the jaguar, chimpanzee, ... a small brain such as small antelope, mongooses and ...
... report that tumor cells display a dramatic reduction of ... to activate the expression of protective microRNAs in the ... issue of Cancer Cell, demonstrates that agents known to ... may function as tumor suppressors in normal cells and ...
... 90 years that cancer cells commonly display altered ... is not completely understood. Now, a new study ... reveals a functional connection between carbohydrate-driven energy production ... inhibition of a specific aspect of glucose metabolism ...
Cached Biology News:Activation of microRNA inhibits cancer gene in human cancer cells 2Researchers attack tumor cells by exploiting dependency on sugar metabolism 2
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... 2010 Halozyme Therapeutics, Inc. (Nasdaq: ... products targeting the extracellular matrix for ... today reported financial results for the third quarter ... http://photos.prnewswire.com/prnh/20100302/LA63139LOGO ) (Logo: http://www.newscom.com/cgi-bin/prnh/20100302/LA63139LOGO ...
... N.J., Nov. 4, 2010 PharmaNet Development Group, Inc., ... pharmaceutical, biotechnology, generic drug and medical device companies, today ... by Company scientists at the 2010 American Association of ... from November 14 -18 at the Ernest N. Morial ...
... seventeen Texas biotechnology companies were awarded more than $35 ... part of the Qualifying Therapeutic Discovery Project Tax Credit ... and the National Institutes of Health. "The ... the ability to continue to invest resources into their ...
Cached Biology Technology:Halozyme Therapeutics Reports Third Quarter 2010 Financial Results 2Halozyme Therapeutics Reports Third Quarter 2010 Financial Results 3Halozyme Therapeutics Reports Third Quarter 2010 Financial Results 4Halozyme Therapeutics Reports Third Quarter 2010 Financial Results 5Halozyme Therapeutics Reports Third Quarter 2010 Financial Results 6Halozyme Therapeutics Reports Third Quarter 2010 Financial Results 7PharmaNet to Present More Than 20 Posters at the 2010 American Association of Pharmaceutical Scientists Annual Meeting 2PharmaNet to Present More Than 20 Posters at the 2010 American Association of Pharmaceutical Scientists Annual Meeting 3Texas Biotech Firms Receive More Than $35 Million in Federal Grants and Credits 2Texas Biotech Firms Receive More Than $35 Million in Federal Grants and Credits 3
Mouse polyclonal antibody raised against a partial recombinant WRB. NCBI Entrez Gene ID = 7485...
...
Mouse monoclonal to Casein Kinase 2 beta ( Abpromise for all tested applications). entrezGeneID: 1460 SwissProtID: P13862...
Mouse monoclonal antibody raised against a partial recombinant FAAH. NCBI Entrez Gene ID = FAAH...
Biology Products: